Skip to main content
Erschienen in: World Journal of Urology 3/2019

19.07.2018 | Original Article

The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study

verfasst von: Stavros Gravas, Michael Samarinas, Konstantina Zacharouli, Anastasios Karatzas, Vasileios Tzortzis, Georgios Koukoulis, Michael Melekos

Erschienen in: World Journal of Urology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the effect of hexanic extract of Serenoa repens (HESr) on prostatic inflammation in patients with diagnosed prostatic inflammation.

Methods

Patients with prostatic inflammation histologically confirmed by TRUS prostatic biopsy were randomized either to receive HESr (320 mg/day) or no treatment. A second biopsy was performed 6 months later according to standard clinical practice. Inflammation was assessed by the Irani’s score and immunohistochemical staining using the CD3, CD4 and CD8 (for T-leucocytes), CD20 (for B-leucocytes) and CD163 (for macrophages) antibodies.

Results

Overall 97 patients were eligible for analysis. In the HESr group the mean inflammation grading and aggressiveness grading score significantly decreased from 1.55 and 1.55 at baseline to 0.79 (p = 0.001) and 0.87 (p = 0.001) at the second biopsy, respectively. In the control group the mean inflammation grading score was 1.44 at first biopsy and 1.23 at the second biopsy. The mean aggressiveness gradings core was 1.09 and 0.89, respectively. No statistical significance was found (p = 0.09 and p = 0.74).The mean decrease in all inflammation scores was statistically higher in the HESr patients compared to controls. The immunohistochemical staining showed a significant change in the expression of the analyzed antibodies for the HESr patients compared to the first biopsy. In the nontreatment group, no significant difference was found at the second biopsy. The change in expression of each antibody in the HESr group was statistical significant compared to control.

Conclusions

HESr seems to reduce prostatic inflammation in terms of histological and immunohistochemical parameters in this specific patients population.
Literatur
1.
Zurück zum Zitat Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS (2008) The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 54(6):1379–1384CrossRefPubMed Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS (2008) The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 54(6):1379–1384CrossRefPubMed
2.
Zurück zum Zitat De Nunzio C, Kramer G, Marberger M et al (2011) The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 60:106–117CrossRefPubMed De Nunzio C, Kramer G, Marberger M et al (2011) The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 60:106–117CrossRefPubMed
3.
Zurück zum Zitat Di Silverio F, Gentile V, De Matteis A et al (2003) Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 43:164–175CrossRefPubMed Di Silverio F, Gentile V, De Matteis A et al (2003) Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 43:164–175CrossRefPubMed
5.
Zurück zum Zitat Buck AC (2004) Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 172:1792–1799CrossRefPubMed Buck AC (2004) Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 172:1792–1799CrossRefPubMed
6.
Zurück zum Zitat De la Taille A (2013) Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl 12:116–122CrossRef De la Taille A (2013) Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl 12:116–122CrossRef
7.
Zurück zum Zitat Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, López Farré A (2003) BPH and inflammation: pharmacological effects of permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 44:549–555CrossRefPubMed Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, López Farré A (2003) BPH and inflammation: pharmacological effects of permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 44:549–555CrossRefPubMed
8.
Zurück zum Zitat Latil A, Pétrissans MT, Rouquet J et al (2015) Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate 75(16):1857–1867CrossRefPubMedPubMedCentral Latil A, Pétrissans MT, Rouquet J et al (2015) Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate 75(16):1857–1867CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J (1997) Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 157(4):1301–1303CrossRefPubMed Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J (1997) Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 157(4):1301–1303CrossRefPubMed
10.
Zurück zum Zitat Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, Maillé P, Allory Y, de la Taille A (2009) Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 69(16):1774–1780CrossRefPubMedPubMedCentral Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, Maillé P, Allory Y, de la Taille A (2009) Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 69(16):1774–1780CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Novara G, Giannarini G, Alcaraz A et al (2016) Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. Eur Urol Focus 2(5):553–561CrossRefPubMed Novara G, Giannarini G, Alcaraz A et al (2016) Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. Eur Urol Focus 2(5):553–561CrossRefPubMed
12.
Zurück zum Zitat Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A et al (2018) Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomized controlled trials and observational studies. BJU Int. https://doi.org/10.1111/bju.14362 (in press) CrossRefPubMed Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A et al (2018) Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomized controlled trials and observational studies. BJU Int. https://​doi.​org/​10.​1111/​bju.​14362 (in press) CrossRefPubMed
Metadaten
Titel
The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study
verfasst von
Stavros Gravas
Michael Samarinas
Konstantina Zacharouli
Anastasios Karatzas
Vasileios Tzortzis
Georgios Koukoulis
Michael Melekos
Publikationsdatum
19.07.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 3/2019
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-018-2409-1

Weitere Artikel der Ausgabe 3/2019

World Journal of Urology 3/2019 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.